# The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer

> **NCT00819247** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 129 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT00819247
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2002-05
- **Final completion:** 2002-08
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00819247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00819247, "The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00819247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*